Oral Arguments in ParkerVision v. Qualcomm Scheduled for November 6, 2023

Oral Arguments in ParkerVision v. Qualcomm Scheduled for November 6, 2023

Accesswire

Published

*JACKSONVILLE, FL / ACCESSWIRE / September 22, 2023 / ParkerVision, Inc. (OTCQB:PRKR*) today announced that the United States Court of Appeals for the Federal Circuit ("CAFC") has scheduled November 6, 2023 for oral arguments in ParkerVision v. Qualcomm (Case No. 2022-1755). ParkerVision (the "Company") filed its notice of appeal in April 2022 following a summary judgment ruling by the U.S. District Court in the Middle District of Florida (Orlando Division) in the Company's patent infringement case against Qualcomm (Case No. 6:14-cv-00687).

ParkerVision's appeal is centered around (i) whether the district court erred in precluding the Company from asserting infringement of receiver patent claims based on a prior patent infringement case against Qualcomm, (ii) whether the district court erred in precluding the Company from offering arguments defending the validity of its 940 patent claims based on decisions of the Patent Trial and Appeal Board with respect to these patent claims, and (iii) whether the district court abused its discretion in striking certain expert testimony based on the expert's decision to rely on evidence produced by Qualcomm rather than less reliable, self-generated simulations.

ParkerVision's appeal requests that the CAFC reverse the district court's judgment and reverse or vacate underlying district court orders on summary judgment, collateral estoppel and Daubert, and remand the case back to district court for trial.

ParkerVision CEO Jeffrey Parker commented, "We have long-awaited this date from the CAFC and are eager to defend our appellate arguments to the CAFC panel."

*About ParkerVision*

ParkerVision, Inc. invents, develops and licenses cutting-edge, proprietary radio-frequency (RF) technologies that enable wireless solution providers to make and sell advanced wireless communication products. ParkerVision is engaged in a number of patent enforcement actions in the U.S. to protect patented rights that it believes are broadly infringed by others. For more information, please visit www.parkervision.com. (PRKR-I)

*Safe Harbor Statement*

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The Company does not guarantee that it will actually achieve the plans, intentions or expectations disclosed in its forward-looking statements and you should not place undue reliance on the Company's forward-looking statements.

Forward-looking statements involve risks and uncertainties, and actual results could vary materially from these forward-looking statements. There are a number of important factors that could cause the Company's actual results to differ materially from those indicated or implied by its forward-looking statements, including those important factors set forth under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 and disclosures in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 and June 30, 2023, filed with the Securities and Exchange Commission. Although the Company may elect to do so at some point in the future, the Company does not assume any obligation to update any forward-looking statement and it disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

*Contact:*

Cindy French
Chief Financial Officer
cfrench@parkervision.com Tony Vignieri
Communications Director
tvignieri@parkervision.com

*SOURCE:* ParkerVision, Inc.
View source version on accesswire.com:
https://www.accesswire.com/786560/oral-arguments-in-parkervision-v-qualcomm-scheduled-for-november-6-2023

Full Article